Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

Similar articles for PubMed (Select 18647256)

1.

Cost-effectiveness of testing for breast cancer susceptibility genes.

Holland ML, Huston A, Noyes K.

Value Health. 2009 Mar-Apr;12(2):207-16. doi: 10.1111/j.1524-4733.2008.00418.x. Epub 2008 Jul 18.

PMID:
18647256
2.

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.

Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR.

Ann Intern Med. 2006 Mar 21;144(6):397-406.

PMID:
16549852
3.

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.

Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI.

J Clin Oncol. 1998 Mar;16(3):979-85.

PMID:
9508180
4.
5.

Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.

Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI.

Cancer J Sci Am. 2000 Jan-Feb;6(1):13-20.

PMID:
10696733
6.

Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.

Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA.

Med Decis Making. 1998 Oct-Dec;18(4):365-75.

PMID:
10372578
7.

Expanding the criteria for BRCA mutation testing in breast cancer survivors.

Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B.

J Clin Oncol. 2010 Sep 20;28(27):4214-20. doi: 10.1200/JCO.2010.28.0719. Epub 2010 Aug 23.

8.

Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.

Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB.

Obstet Gynecol. 2013 Jan;121(1):14-24. doi: http://10.1097/AOG.0b013e3182783c2f.

PMID:
23232752
9.

Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2.

Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI.

J Clin Oncol. 1999 Feb;17(2):494-500.

PMID:
10080590
10.

Costs and benefits of diagnosing familial breast cancer.

Heimdal K, Maehle L, Møller P.

Dis Markers. 1999 Oct;15(1-3):167-73.

11.

Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.

Norum J, Hagen AI, Maehle L, Apold J, Burn J, Møller P.

Eur J Cancer. 2008 May;44(7):963-71. doi: 10.1016/j.ejca.2008.02.025. Epub 2008 Mar 24.

PMID:
18362067
12.

Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.

Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI.

J Clin Oncol. 2002 May 15;20(10):2520-9.

PMID:
12011131
13.
14.

Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.

Schrag D, Kuntz KM, Garber JE, Weeks JC.

N Engl J Med. 1997 May 15;336(20):1465-71. Erratum in: N Engl J Med 1997 Aug 7;337(6):434.

15.

Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.

van Roosmalen MS, Verhoef LC, Stalmeier PF, Hoogerbrugge N, van Daal WA.

J Clin Oncol. 2002 Apr 15;20(8):2092-100.

PMID:
11956270
16.

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.

Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.

J Natl Cancer Inst. 2014 Nov 30;107(1):380. doi: 10.1093/jnci/dju380. Print 2015 Jan.

17.

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.

Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G.

J Clin Oncol. 2002 Jun 1;20(11):2701-12.

PMID:
12039933
18.

Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.

Morgan D, Sylvester H, Lucas FL, Miesfeldt S.

Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4.

PMID:
19347608
19.

Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.

Cott Chubiz JE, Lee JM, Gilmore ME, Kong CY, Lowry KP, Halpern EF, McMahon PM, Ryan PD, Gazelle GS.

Cancer. 2013 Mar 15;119(6):1266-76. doi: 10.1002/cncr.27864. Epub 2012 Nov 26.

20.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk